A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.


BACKGROUND The likelihood of distant recurrence in patients with breast cancer who have no involved lymph nodes and estrogen-receptor-positive tumors is poorly defined by clinical and histopathological measures. METHODS We tested whether the results of a reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assay of 21 prospectively selected genes in paraffin-embedded tumor tissue would correlate with the likelihood of distant recurrence in patients with node-negative, tamoxifen-treated breast cancer who were enrolled in the National Surgical Adjuvant Breast and Bowel Project clinical trial B-14. The levels of expression of 16 cancer-related genes and 5 reference genes were used in a prospectively defined algorithm to calculate a recurrence score and to determine a risk group (low, intermediate, or high) for each patient. RESULTS Adequate RT-PCR profiles were obtained in 668 of 675 tumor blocks. The proportions of patients categorized as having a low, intermediate, or high risk by the RT-PCR assay were 51, 22, and 27 percent, respectively. The Kaplan-Meier estimates of the rates of distant recurrence at 10 years in the low-risk, intermediate-risk, and high-risk groups were 6.8 percent (95 percent confidence interval, 4.0 to 9.6), 14.3 percent (95 percent confidence interval, 8.3 to 20.3), and 30.5 percent (95 percent confidence interval, 23.6 to 37.4). The rate in the low-risk group was significantly lower than that in the high-risk group (P<0.001). In a multivariate Cox model, the recurrence score provided significant predictive power that was independent of age and tumor size (P<0.001). The recurrence score was also predictive of overall survival (P<0.001) and could be used as a continuous function to predict distant recurrence in individual patients. CONCLUSIONS The recurrence score has been validated as quantifying the likelihood of distant recurrence in tamoxifen-treated patients with node-negative, estrogen-receptor-positive breast cancer.

Extracted Key Phrases

7 Figures and Tables

Citations per Year

24,781 Citations

Semantic Scholar estimates that this publication has 24,781 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Paik2004AMA, title={A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.}, author={Soonmyung Paik and Steven Shak and Gong Tang and Chungyeul Kim and Joffre B. Baker and Maureen T. Cronin and Frederick L. Baehner and Michael G. Walker and Drew Watson and Taesung Park and William Hiller and Edwin R. Fisher and Donald Lawrence Wickerham and John B Bryant and Norman Wolmark}, journal={The New England journal of medicine}, year={2004}, volume={351 27}, pages={2817-26} }